Meta Pixel

News and Announcements

Zahara x Comma: The purchase-to-pay solution to help you gain control of business spend

  • Published May 19, 2022 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

The significant benefits of accounts payable automation are nothing new, but they are changing and adapting to the latest innovations in financial technology. AP automation and purchase to pay solutions are bringing your finance team even faster and more secure processes. Businesses who desire to remain competitive have already shifted from manual, paper processes that became tedious and outdated. The pandemic accelerated a shift into digital transformation that was needed for businesses to adapt to modern trends and meet the needs of their clients. For many companies, this meant adopting cloud-based software that allowed them to enhance the way they do business without overhauling their current process.

Register Interest

What is Zahara?

  • Zahara is an all-in-one accounts payable automation solution that helps finance teams process invoices faster and gain control over what they spend. Invoices are emailed into Zahara, where they are read automatically, routed out for approval and matched against purchase orders. In short, Zahara speeds up processing bills, ready to be paid.

What is Comma?

  • This is where Comma steps in. Coming soon, Comma will be natively embedded into the Zahara software as a new feature, Pay with Comma, which allows businesses to pay all outstanding invoices with the click of a button. This removes the need to create an account with Comma, move to a different website or onboard a new software. Instead, Zahara users will be pushed to their current bank account where all invoices can be bulk paid in one transaction; powered by Open Banking.

Read more here

Register Interest

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now